[ad_1]
ReNeuron Group PLC (LON: RENE) Michael Hunt talks to Andrew Scott of Proactive London after announcing that the first group of patients receiving cell therapy for a blindness-causing disease saw "continuous and visible improvement."
The data come from a Phase IIa study on the treatment of retinitis pigmentosa by human retinal progenitor cells (hRPC).
Source link
